Anamorelin
Pharmaceutical
Anamorelin is an orally active, small-molecule agonist of the ghrelin/growth hormone secretagogue receptor (GHSR-1a). It was developed for cancer cachexia — the loss of appetite, body weight and muscle mass that accompanies many advanced cancers. By mimicking ghrelin at its receptor, anamorelin is intended to stimulate appetite and promote gains in body weight and lean (muscle) mass. Regulatory status differs sharply by region. Anamorelin was approved in Japan on 11 December 2020 for cancer cachexia in patients with non-small cell lung cancer (NSCLC), gastric, pancreatic and colorectal cancer. In the European Union, the EMA's CHMP recommended refusing marketing authorisation for Adlumiz (anamorelin) for anorexia, cachexia or unintended weight loss in NSCLC in May 2017, confirmed that refusal on re-examination in September 2017, and the refusal was issued in November 2017. The committee judged the effect on lean body mass marginal, found no proven effect on handgrip strength or quality of life, and, after inspecting trial sites, considered safety data inadequately recorded. Anamorelin is not an FDA-approved medicine in the United States. The core evidence comes from the ROMANA 1 and ROMANA 2 phase 3 trials (979 patients with inoperable stage III/IV NSCLC and cachexia, randomised 2:1 to anamorelin 100 mg once daily or placebo for 12 weeks). Anamorelin increased lean body mass (median +0.99 kg vs −0.47 kg in ROMANA 1; +0.65 kg vs −0.98 kg in ROMANA 2) but did not improve handgrip strength. A 12-week safety extension (ROMANA 3) found adverse-event rates similar to placebo. Japanese trials reported comparable lean-mass gains in NSCLC and in gastrointestinal cancers. Anamorelin shares its target with ghrelin, the approved diagnostic agent macimorelin, the investigational prokinetic relamorelin and research secretagogues such as ibutamoren and ipamorelin. Cachexia is a serious, clinician-managed condition; standard oncology and nutritional/supportive care remain the foundation of treatment.
Specifications
| Origin / Manufacturer | Synthetic (orally bioavailable small-molecule GHSR-1a agonist) |
| Regulatory Status | Approved in Japan (December 2020) for cancer cachexiaEU marketing authorisation refused (EMA, 2017)Not FDA-approved (US) |
| Active Components | Anamorelin hydrochloride |
| Storage | Per manufacturer labeling (Japan) |
| Shelf Life | Per manufacturer labeling |
| Form Factor | Oral tablet |
Clinical Evidence
Clinical report reference
Clinical report reference
Clinical report reference
Clinical report reference
Clinical report reference
Frequently Asked Questions
Sources & References
Every clinical claim on this page traces to a primary peer-reviewed source.
- 1Temel JS, Abernethy AP, Currow DC, et al.. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. The Lancet Oncology. 2016;17(4):519-531. doi:10.1016/S1470-2045(15)00558-6 PMID:26906526
- 2Currow D, Temel JS, Abernethy A, et al.. ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. Annals of Oncology. 2017;28(8):1949-1956. doi:10.1093/annonc/mdx192 PMID:28472437
- 3Katakami N, Uchino J, Yokoyama T, et al.. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer. 2018;124(3):606-616. doi:10.1002/cncr.31128 PMID:29205286
- 4Hamauchi S, Furuse J, Takano T, et al.. A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia. Cancer. 2019;125(23):4294-4302. doi:10.1002/cncr.32406 PMID:31415709
- 5Wakabayashi H, Arai H, Inui A. The regulatory approval of anamorelin for treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers. Journal of Cachexia, Sarcopenia and Muscle. 2021;12(1):14-16. doi:10.1002/jcsm.12675 PMID:33382205
- 6European Medicines Agency. Adlumiz (anamorelin): refusal of the marketing authorisation. European Medicines Agency. 2017.
Reviewed by
Clinical Research Review Board
Pharmacology & Endocrinology Review
All clinical claims cross-checked against primary sources. Read our editorial policy →
Related Peptides
Ghrelin
Endogenous Hormone
The body's own 28-amino-acid 'hunger hormone' released mainly by the stomach — the only well-established circulating peptide that stimulates appetite, and the natural ligand for the growth hormone secretagogue receptor (GHSR-1a).
Ibutamoren (MK-677)
Research-Grade
An oral, non-peptide growth hormone secretagogue that mimics ghrelin at the GHSR-1a receptor — produces sustained GH and IGF-1 elevation without injections. Extensively studied in human trials.
Ipamorelin
Research-Grade
The most selective GHRP (growth-hormone-releasing peptide) — amplifies GH pulses via ghrelin/GHSR receptor without meaningful cortisol, prolactin, or aldosterone crosstalk.
Macimorelin
Pharmaceutical
An FDA-approved oral ghrelin receptor agonist used as a diagnostic test for adult growth hormone deficiency — the first and only oral GH stimulation test approved in the United States.
Relamorelin
Pharmaceutical
An investigational injectable ghrelin-receptor (GHSR-1a) agonist studied as a prokinetic for diabetic gastroparesis. It accelerates gastric emptying and showed positive phase 2b results, but is not approved anywhere — research-only.